Live Breaking News & Updates on Dougall advisors

Stay informed with the latest breaking news from Dougall advisors on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Dougall advisors and stay connected to the pulse of your community

Hummingbird Diagnostics GmbH: Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

-Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy- -Blood-based test holds potential for broad applicability

Bruno-steinkraus , Petros-christopoulos , Lungenclinic-grosshansdorf , Matthew-corcoran , Kostenloser-wertpapierhandel , Michael-thomas , Jochen-kohlhaas , Martin-reck , Thoraxklinik-at-heidelberg-university-hospital , Diagnostics-gmbh , Precision-oncology , Chief-scientific-officer

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced today it exercised its option with Lausanne University Hospital (Centre Hospitalier Universitaire

United-kingdom , Switzerland , London , City-of , Swiss , Patrice-jichlinski , Ilaria-lucca , Matthew-corcoran , Livija-deban , Kristen-albright , Kostenloser-wertpapierhandel , Denise-nardelli-haefliger

Neutron Therapeutics, Inc.: Neutron Therapeutics and Cosylab Announce Strategic Collaboration to Bring Boron Neutron Capture Therapy to Patients

Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for

Ljubljana , Slovenia-general- , Slovenia , Boston , Massachusetts , United-states , Carolyn-noyes , Kostenloser-wertpapierhandel , Liz-reczek , Cosylab-oncologyone , Neutron-therapeutics-inc , Neutron-therapeutics

Numab Therapeutics AG: Numab and 3SBio's Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option

Taiwan , Shanghai , China , Hong-kong , Shenzhen , Guangdong , Shenyang , Liaoning , Italy , Zurich , Züsz , Switzerland

Prokarium Appoints Industry Veteran Thomas Eldered as Chairman of the Board

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Thomas Eldered as Chairman of the Board. Thomas Eldered succeeds Steve

United-states , India , United-kingdom , Israel , London , City-of , America , Kristen-albright , Mario-brkulj , Kostenloser-wertpapierhandel , Thomas-eldered , Steve-chatfield

KIYATEC clinical study data shows test accurately predicts brain cancer patient response

KIYATEC clinical study data shows test accurately predicts brain cancer patient response
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Lauren-arnold , Matthew-gevaert , Clinical-services , Us-senate , Kiyatec-inc , Drug-development-services , Neuro-oncology-advances , Glioblastoma-awareness-day , Dougall-advisors , லாரன்-அர்னால்ட் , மருத்துவ-சேவைகள்

Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies

(0)
Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women's health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo's therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US.
"The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinology mechanism provides an opportunity for superior management of endometriosis," commented Risto Lammintausta, CEO of Forendo. "We are now looking forward to expanding our clinical development program into the US and potentially into complementary women's health indications, in addition to endometriosis. The upcoming Phase 2 program will transition the clinical evaluation of FOR-6219 into symptomatic patients and deepen our understanding of the drug's impact on the disease biology and endometriotic tissue."

Finland , Kostenloser-wertpapierhandel , Forendo-pharma , Caroline-rufo , Risto-lammintausta , Linkedin , Twitter , Karolinska-development , Novartis-venture-fund , Novartis , Novo-seeds , Vesalius-biocapital